Ondine Biomedical, Inc. (OBI) Price & Analysis

Compare

7 Followers

OBI Stock Chart & Stats

Day’s Range― - ―

52-Week Range5.50p - 13.30p

Previous CloseN/A

Volume7.12K

Average Volume (3M)90.55K

Market Cap

£37.67M

Enterprise ValueN/A

Total Cash (Recent Filing)£2.98M

Total Debt (Recent Filing)C$541.00K

Price to Earnings (P/E)―

Beta0.42

Next Earnings

Sep 30, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.02

Shares Outstanding443,233,200

10 Day Avg. Volume85,468

30 Day Avg. Volume90,549

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

£55.00

Price Target Upside547.06% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering0

Ondine Biomedical, Inc. News

PremiumCompany Announcements

Ondine Biomedical Reports 70% Revenue Growth and Strategic Expansion in 2024

9d ago

PremiumCompany Announcements

Ondine Biomedical Joins CAN Health Network to Boost Infection Prevention Innovation

12d ago

PremiumCompany Announcements

Ondine Biomedical Appoints Alan Thomas as Interim CFO

15d ago

PremiumCompany Announcements

Ondine Biomedical to Announce 2024 Financial Results and Host Investor Presentation

16d ago

PremiumCompany Announcements

Ondine Biomedical’s Steriwave Promises Significant Cost Savings for UK Hospitals

2M ago

PremiumCompany Announcements

Ondine Biomedical’s Steriwave Technology Undergoes Study at Swiss Hospital

2M ago

PremiumCompany Announcements

Ondine Biomedical’s Steriwave Technology Undergoes Study at University Hospital Zurich

2M ago

PremiumCompany Announcements

Ondine Biomedical’s Steriwave Achieves 71% Reduction in Surgical Infections at UK NHS Trust

2M ago

See All GB:OBI News

See All News >

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

36.76% Insiders

―

Mutual Funds

― Other Institutional Investors

63.24% Public Companies and

Individual Investors

Detailed Ownership Overview >

OBI FAQ

What was Ondine Biomedical, Inc.’s price range in the past 12 months?

Ondine Biomedical, Inc. lowest share price was 5.50p and its highest was 13.30p in the past 12 months.

What is Ondine Biomedical, Inc.’s market cap?

Ondine Biomedical, Inc.’s market cap is £37.67M.

When is Ondine Biomedical, Inc.’s upcoming earnings report date?

Ondine Biomedical, Inc.’s upcoming earnings report date is Sep 30, 2025 which is in 129 days.

How were Ondine Biomedical, Inc.’s earnings last quarter?

Ondine Biomedical, Inc. released its earnings results on May 15, 2025. The company reported -0.021p earnings per share for the quarter, missing the consensus estimate of N/A by -0.021p.

Is Ondine Biomedical, Inc. overvalued?

According to Wall Street analysts Ondine Biomedical, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ondine Biomedical, Inc. pay dividends?

Ondine Biomedical, Inc. does not currently pay dividends.

What is Ondine Biomedical, Inc.’s EPS estimate?

Ondine Biomedical, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Ondine Biomedical, Inc. have?

Ondine Biomedical, Inc. has 443,233,200 shares outstanding.

What happened to Ondine Biomedical, Inc.’s price movement after its last earnings report?

Ondine Biomedical, Inc. reported an EPS of -0.021p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.714%.

Which hedge fund is a major shareholder of Ondine Biomedical, Inc.?

Currently, no hedge funds are holding shares in GB:OBI

Ondine Biomedical, Inc. Stock Smart Score

Underperform

Fundamentals

Return on Equity

-430.02%

Trailing 12-Months

Asset Growth

108.68%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Ondine Biomedical, Inc.

Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company's lead product is Steriwave, a photodisinfection based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces SARS-CoV-2 titre and transmission; a solution for treatment of chronic rhinosinusitis; OND1002, a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and OND1003, a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.

OBI Stock 12 Month Forecast

Average Price Target

55.00p

▲( 547.06% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"5p","56":"56p","17.75":"17.75p","30.5":"30.5p","43.25":"43.3p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">55.00p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">55.00p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">55.00p</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,17.75,30.5,43.25,56],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2022","6":"Sep<br/>2022","9":"Jul<br/>2024","12":"Feb<br/>2025","25":"Feb<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.5,15.76923076923077,19.03846153846154,22.307692307692307,25.576923076923077,28.846153846153847,32.11538461538461,35.38461538461539,38.65384615384615,41.92307692307692,45.19230769230769,48.46153846153846,51.730769230769226,{"y":55,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.5,15.76923076923077,19.03846153846154,22.307692307692307,25.576923076923077,28.846153846153847,32.11538461538461,35.38461538461539,38.65384615384615,41.92307692307692,45.19230769230769,48.46153846153846,51.730769230769226,{"y":55,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.5,15.76923076923077,19.03846153846154,22.307692307692307,25.576923076923077,28.846153846153847,32.11538461538461,35.38461538461539,38.65384615384615,41.92307692307692,45.19230769230769,48.46153846153846,51.730769230769226,{"y":55,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":47,"date":1648771200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":44.5,"date":1651363200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":43,"date":1654041600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":43.5,"date":1656633600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":37.75,"date":1659312000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":39.5,"date":1661990400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":39.5,"date":1661990400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.5,"date":1672531200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.25,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.75,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.75,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.75,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.5,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >